Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Laura Schoch, C.R.N.P., is an internal medicine provider at Johns Hopkins Community Physicians. N.P. Schoch earned her masters of science in nursing (MSN) in 2014 from the University of Maryland (IMD) with an adult and gerontology focus. She also completed an oncology certificate program while at UMD, and was a recipient of the American Cancer Society Graduate Scholarship in Cancer Nursing Practice in 2012. N.P. Schoch is a licensed nurse practitioner in Maryland. N.P. Schoch has extensive oncology experience and is especially interested in cancer prevention and survivorship. She is excited to partner with her patients to promote health, prevent disease and facilitate optimal aging across the lifespan. She lives with her husband, two daughters, one cat and many plants in Ellicott City. Ms. Schoch is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Classical Hodgkin Lymphoma, T-Cell Lymphoma, Marginal Zone Lymphoma (MZL), and Smoldering Multiple Myeloma.

Dr. Shin specializes Barrett's esophagus, pancreatobiliary disease (pancreatic cyst, family history of pancreatic cancer), GI malignancy, and advanced endoscopy, including endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS). Dr. Shin is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Bile Duct Stricture, Endoscopy, and Pancreaticoduodenectomy.

Stuart Selonick is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Selonick is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Idiopathic Neutropenia, and Lung Cancer. Dr. Selonick is currently accepting new patients.

Jason Taksey is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Taksey is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Urothelial Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and WT1-Related Wilms Tumor Syndromes. Dr. Taksey is currently accepting new patients.

Jose Mendoza is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Mendoza is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Familial Colorectal Cancer. Dr. Mendoza is currently accepting new patients.

Ari Elman is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Elman has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Myelodysplastic Syndrome (MDS). Dr. Elman is currently accepting new patients.

Nicholas Demonaco is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Demonaco is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Pulmonary Embolism, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Anemia. Dr. Demonaco is currently accepting new patients.

Rita Gupta is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Gupta is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Paget Disease of the Breast, and Breast Cancer. Dr. Gupta is currently accepting new patients.

Jeanine Werner is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Werner is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Virilizing Ovarian Tumor. Dr. Werner is currently accepting new patients.

Peter Graze is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Graze is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Graze is currently accepting new patients.

Richard Chasen is a Gastroenterologist in Columbia, Maryland. Dr. Chasen is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Gastric Dysmotility, Gastroesophageal Reflux Disease (GERD), Indigestion, and Diverticular Disease.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

Joseph Haggerty is a Hematologist Oncology specialist and a Hematologist in Laurel, Maryland. Dr. Haggerty has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Saddle Pulmonary Embolism, and Paget Disease of the Breast. Dr. Haggerty is currently accepting new patients.